The antiviral Drug Company  

 

The main focus of the company is to develop a new First-in-Class anti-HIV compound which inhibits the pre-integration complex.

Our project is to develop sustained and safe release formulation.

Such a drug candidate could significantly reduce the cost of treatment and improve treatment compliance and patient quality of life.

The competitive advantages of this drug candidate are:

  • The long term Pre-exposure prophylaxis (PrEP) : 3 months or 6 months protection after each injection
  • The fact that it can be add on fixed dose in combination with anti-HIV drugs

 

News :

06/02/2012 : RFS Pharma and Genoscience Pharma enter worlwide license agreement with BiolineRX to develop and commercialize Hepatitis C virus protease inhibitor.

 

24/01/2012  : BiolineRX Ltd has signed a worldwide, exclusive license agreement with Genoscience to develop and commercialize its BL-8020 drug for the treatment of hepatitis C.

 

Abstract to be presented during the CROI congress. A POTENT CYCLIC PEPTIDE INHIBITOR OF HIV-1 PRE-INTEGRATION COMPLEX FORMATION: A NEW HIV DRUG CANDIDATE

 

 

 

© 2012